A recent study shows that patients with a specific molecular subtype of diffuse large B-cell lymphoma (DLBCL) are more likely to respond to ibrutinib (Imbruvica) than patients with another molecular subtype of the disease.
Study shows promise of precision medicine for most common type of lymphoma
A recent study shows that patients with a specific molecular subtype of diffuse large B-cell lymphoma (DLBCL) are more likely to respond to ibrutinib (Imbruvica) than patients with another molecular subtype of the disease.
Diffuse large B-cell lymphoma (DLBCL) – an aggressive (fast-growing) lymphoma – is the most common type of non-Hodgkin’s lymphoma (NHL).
The phase II trial, conducted by the National Cancer Institute (NCI) and Pharmacyclics, showed that patients with the activated B-cell-like (ABC) subtype of DLBCL were more likely to respond to ibrutinib than patients with the germinal center B-cell-like (GCB) subtype of DLBCL.
